Buniva G, Dubini A, Nicolis F G
Int J Clin Pharmacol Biopharm. 1977 Sep;15(9):438-43.
The possible interaction of acetylsalicylic acid (ASA) and diftalone (DIF), a new anti-inflammatory drug, was studied in 6 volunteers. All subjects received each of the following three treatments: ASA 1 g, DIF 0.5 g, ASA 1 g plus DIF 0.5 g at 4-day intervals (stage 1 of the study). In stage II of the same study, each subject received ASA 1 g plus DIF 0.5 g in three different occasions 1 week apart; after a 7-day pre-treatment with either DIF 0.25 g b.i.d., or ASA 0.5 g b.i.d., or DIF 0.25 g b.i.d. plus ASA 0.5 g b.i.d. A total of four different comparisons were made. After pre-treatment with DIF, but not after pre-treatment with DIF plus ASA, the peak level of salicylate was significantly reduced by about 15%. No other evidence of interaction was found.
在6名志愿者身上研究了乙酰水杨酸(ASA)与一种新型抗炎药物双他龙(DIF)之间可能的相互作用。所有受试者均接受了以下三种治疗,每种治疗间隔4天:1克ASA、0.5克DIF、1克ASA加0.5克DIF(研究的第一阶段)。在同一研究的第二阶段,每个受试者在三个不同的场合接受1克ASA加0.5克DIF,每次间隔1周;在分别用0.25克DIF每日两次、0.5克ASA每日两次、0.25克DIF每日两次加0.5克ASA每日两次进行7天预处理之后。总共进行了四项不同的比较。在用DIF预处理后,但在用DIF加ASA预处理后未出现这种情况,水杨酸盐的峰值水平显著降低了约15%。未发现其他相互作用的证据。